Last reviewed · How we verify

Omeprazole Low dose

Damascus Hospital · FDA-approved active Small molecule Quality 5/100

Omeprazole Low dose is a Small molecule drug developed by Damascus Hospital. It is currently FDA-approved.

Omeprazole Low Dose, marketed by Damascus Hospital, is a proton pump inhibitor with a well-established presence in the treatment of acid-related disorders. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market stability. The primary risk lies in the potential increase in generic competition following the patent expiry, which could erode market share and revenue.

At a glance

Generic nameOmeprazole Low dose
SponsorDamascus Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Omeprazole Low dose

What is Omeprazole Low dose?

Omeprazole Low dose is a Small molecule drug developed by Damascus Hospital.

Who makes Omeprazole Low dose?

Omeprazole Low dose is developed and marketed by Damascus Hospital (see full Damascus Hospital pipeline at /company/damascus-hospital).

What development phase is Omeprazole Low dose in?

Omeprazole Low dose is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing